IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome
Chen, Y.; Liu, K.; Xu, L.; Chen, H.; Liu, D.; Zhang, X.; Shi, H.; Han, W.; Wang, Y.; Zhao, T.; Wang, J.; Wang, J.; Huang, X.
关键词Myelodysplastic Syndrome Hematopoietic Sct Allogeneic Hla Haploidentical Mismatched
刊名BONE MARROW TRANSPLANTATION
2010-08-01
DOI10.1038/bmt.2009.351
45期:8页:1333-1339
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation
研究领域[WOS]Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation
关键词[WOS]BONE-MARROW-TRANSPLANTATION ; LEUKEMIA WORKING PARTY ; IDENTICAL SIBLINGS ; DONOR ; BLOOD ; CYCLOPHOSPHAMIDE ; CHEMOTHERAPY ; BUSULFAN ; RELAPSE ; GRAFTS
英文摘要

Allogeneic hematopoietic SCT (HSCT) is currently the only curative treatment for myelodysplastic syndrome (MDS). However, many patients cannot find an HLA-matched donor. We have developed a new protocol for HLA-mismatched (including haploidentical) HSCT using G-CSF-primed BM plus G-CSF-mobilized PBSCs without in vitro T-cell depletion. A total of 36 patients diagnosed with high-risk MDS (RAEB (refractory anemia with excess blasts) or RAEBt (RAEB in transformation)) underwent transplantation from HLA-mismatched family donors. All patients achieved sustained myeloid engraftment. The cumulative incidence of grades II-IV acute GVHD (aGVHD) was 60% and that of grades III and IV aGVHD was 15%. The 2-year cumulative incidence of chronic GVHD was 56%. After a median follow-up of 17 months, 4 patients had relapsed and died and 25 patients were still alive. The 2-year probability of leukemia-free survival (LFS) was 65%. Patients transplanted within 7 months of diagnosis had better LFS (89 vs 43%). Severe aGVHD decreased the LFS significantly by increasing non-relapse mortality (NRM). This study confirms that HLA-mismatched HSCT is a treatment option for MDS. Patients with high-risk MDS benefit from receiving HSCT early in the course of the disease. Bone Marrow Transplantation (2010) 45, 1333-1339; doi: 10.1038/bmt.2009.351; published online 11 January 2010

语种英语
WOS记录号WOS:000280777400011
项目编号2008BAI61B02 ; 30725038 ; IRT0702
资助机构Key Projects in the National Science &amp ; Technology Pillar Program ; National Science Foundation for Distinguished Young Scholars of China ; Innovation team by the Ministry of Education
引用统计
被引频次:21[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/50111
专题北京大学第二临床医学院_血液科
医学人文研究院/公共教学部_哲学与社会科学系
北京大学第二临床医学院_神经内科
作者单位Peking Univ, Inst Hematol, Peoples Hosp, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Chen, Y.,Liu, K.,Xu, L.,et al. HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome[J]. BONE MARROW TRANSPLANTATION,2010,45(8):1333-1339.
APA Chen, Y..,Liu, K..,Xu, L..,Chen, H..,Liu, D..,...&Huang, X..(2010).HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome.BONE MARROW TRANSPLANTATION,45(8),1333-1339.
MLA Chen, Y.,et al."HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome".BONE MARROW TRANSPLANTATION 45.8(2010):1333-1339.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Chen, Y.]的文章
[Liu, K.]的文章
[Xu, L.]的文章
百度学术
百度学术中相似的文章
[Chen, Y.]的文章
[Liu, K.]的文章
[Xu, L.]的文章
必应学术
必应学术中相似的文章
[Chen, Y.]的文章
[Liu, K.]的文章
[Xu, L.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。